All news

CanniMed Therapeutics Inc. reports financial results for Q3 2017

Sales of $4.8 million in the quarter were 80 per cent higher than in the comparable period of the prior year and were 29 per cent higher than the second quarter of 2017.

Ohio Lawmaker Urges Rescheduling of Cannabis to Allow for Research

Few drugs scheduled as a Schedule I drug – that is, a drug without medical benefit and with a high potential for abuse and addiction – have been as controversial lately as marijuana.

Senior citizens embrace medicinal cannabis: use up 250%

Far from a gateway drug, marijuana helps today’s senior citizens exit the vicious cycle of pharmaceuticals and addiction. Although marijuana was once considered a dangerous recreational drug by many senior citizens, today’s elderly are among the fastest growing demographic within the industry.

Tremendous opportunity in legal cannabis market

Tremendous opportunity in legal cannabis market

Companies need to start thinking about the therapeutic benefits

Medical cannabis licence granted to WA company AusCann

AUSTRALIAN drug regulators have granted what is believed to be the first licence to manufacture and supply medical cannabis in WA.

Is GW Pharma now the future of cannabis-based drugs?

GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) shares initially jumped Monday after disappointing data from a leading drug candidate sent shares of Zynerba Pharmaceuticals Inc

Queensland Bauxite gets results from winter cannabis crop

Queensland Bauxite (ASX:QBL) - Potential market updates are expected regarding production, marketing and distribution agreements

Burnley cannabis food supplement store 'will be first in the UK'

A shop thought to be the first in the UK dedicated to a cannabis compound with claimed health benefits is due to open in East Lancashire.

Creso Pharma sign exclusive agreement with Virbac

The Swiss launch of CPH’s proprietary formulated hemp-based complementary feed products for companion animals, anibidiol® 1.25 and anibidiol® 2.5, is planned for the fourth quarter of this year.


Company Developing Cannabinoid-Based Drug Therapy for Concussions Completes Reverse Takeover

A preclinical research and development company that is developing a proprietary cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury, has just completed a reverse takeover.